Evidence map›Paper›PMID 34897998›Full record

ArticleProteomics2022

BoxCar and shotgun proteomic analyses reveal molecular networks regulated by UBR5 in prostate cancer.

Yiwu Yan, Bo Zhou, Yeon-Joo Lee, Sungyong You, Michael R Freeman, Wei Yang

Open access · greenAbstract read
In one paragraph

Article in Proteomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yiwu YanDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Bo ZhouDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Yeon-Joo LeeDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-6605-8761
Sungyong YouDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Michael R FreemanDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Wei YangDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0003-2575-3570
Cedars-Sinai Medical Center · US

Funding

Racial Differences in Prostate Cancer Molecular SubtypingR01CA220327 · NCI · CEDARS-SINAI MEDICAL CENTER · PI Stephen Jay Freedland, Michael R. Freeman · 2018 to 2026
$3.1M
Mechanisms of Prostate Cancer MetastasisR01CA271750 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FREEMAN, MICHAEL R., GARRAWAY, ISLA PEARL · 2021 to 2025
$2.2M
High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancerR01CA218526 · NCI · CEDARS-SINAI MEDICAL CENTER · PI DI VIZIO, DOLORES, HURLEY, PAULA JILL · 2017 to 2021
$2.0M
NCI NIH HHS R01 CA218526NCI NIH HHS R01 CA220327NCI NIH HHS R01 CA271750
6 · The paper itself

Abstract

Prostate cancer (PC) is a major health and economic problem in industrialized countries, yet our understanding of the molecular mechanisms of PC progression and drug response remains limited. Accumulating evidence showed that certain E3 ubiquitin ligases such as SIAH2, RNF7, and SPOP play important roles in PC development and progression. However, the roles and mechanisms of other E3s in PC progression remain largely unexplored. Through an integration analysis of clinical genomic and transcriptomic profiles of PC tumors, this study identified UBR5 as a top PC-relevant E3 ubiquitin ligase whose expression levels are strongly associated with PC progression and aggressiveness. BoxCar and shotgun proteomic analyses of control and UBR5-knockdown PC3 cells complementarily identified 75 UBR5-regulated proteins. Bioinformatic analysis suggested that the 75 proteins form four molecular networks centered around FANCD2, PAF1, YY1, and LAMB3 via direct protein-protein interactions. Experimental analyses demonstrated that UBR5 associates with and downregulates two key DNA damage repair proteins (XRCC3 and FANCD2) and confers PC cell sensitivity to olaparib, a PARP inhibitor in clinical use for cancer therapy. This study represents the first application of BoxCar in PC research, provides new insights into the molecular functions of UBR5 in PC, and suggests that PC patients with UBR5-high tumors may potentially benefit from PARP inhibitor treatment.

Indexed as

Antineoplastic AgentsProstatic NeoplasmsHumansMaleNuclear ProteinsProteomicsRepressor ProteinsTranscription FactorsUbiquitin-Protein LigasesAntineoplastic AgentsNuclear ProteinsPAF1 protein, humanRepressor ProteinsSPOP protein, humanTranscription FactorsUbiquitin-Protein LigasesUBR5 protein, humanBoxCarprostate cancerproteomicsshotgunUBR5

Identifiers

PMID34897998
PMCPMC8844095
OpenAlexW4200368275

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.